ACU-193 is under clinical development by Acumen Pharmaceuticals and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACU-193’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ACU-193 overview

ACU-193 is under development for the treatment of Alzheimer's disease and mild cognitive impairment due to AD and mild dementia due to Alzheimer's disease. It is a fully-humanized, IgG2 murine monoclonal antibody capable of selective binding to soluble abeta oligomers/ADDLs (amyloid precursor protein). It is administered through the intravenous route as infusion. ADDLs are highly ordered aggregates of amyloid-beta 1-42 peptides. It is developed based on ADDL-Select technology.

Acumen Pharmaceuticals overview

Acumen Pharmaceuticals (Acumen) is a developer of therapeutics and diagnostics for the treatment of Alzheimer’s disease and related neurodegenerative conditions. The company discovers and develops ADDL-Select antibodies that target soluble amyloid-beta oligomers that inhibit nerve function, trigger early memory deficits, initiate nerve cell degeneration and downstream pathological events in Alzheimer’s. Its lead candidate include ACU-193, an anti-ADDL antibody which is in preclinical development stage. Acumen also uses an ultra-high sensitivity assay to measure soluble amyloid-beta oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials.The company owns intellectual property for soluble A-beta oligomers, ADDLs and related therapeutics and diagnostics. Acumen is headquartered in Livermore, California, the US.

For a complete picture of ACU-193’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.